Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

DOI Full Paper Access

193

Citations

14

References

2021

Year

Unknown Author(s)

The Lancet Infectious Diseases

Brii-196 Plus Brii-198Monoclonal Antibody TherapiesCovid-19 PandemicImmunologyClinical TrialsAntiviral TherapyVaccine EfficacyImmunotherapyMedicineCovid-19

References

	Year	Citations

Page 1